Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma

<p>Extended Data relating to Main Figure 2/Assessment of ALDH1A1+ cells from primary, treatment-naive glioblastoma. A, Bar plot shows ALDH-bright (ALDHbr) vital cells from two additional paired cases of naive vs. experimental (TMZ→eR) and clinical (cR) relapse. Data as mean ± SD. p values by o...

Descrizione completa

Salvato in:

Dettagli Bibliografici
Autore principale:	Sied Kebir (15048732) (author)
Altri autori:	Vivien Ullrich (15048735) (author), Pia Berger (15048738) (author), Celia Dobersalske (15048741) (author), Sarah Langer (15048744) (author), Laurèl Rauschenbach (15048747) (author), Daniel Trageser (15048750) (author), Andreas Till (15048753) (author), Franziska K. Lorbeer (15048756) (author), Anja Wieland (15048759) (author), Timo Wilhelm-Buchstab (15048762) (author), Ashar Ahmad (15048765) (author), Holger Fröhlich (8724576) (author), Igor Cima (15048768) (author), Shruthi Prasad (15048771) (author), Johann Matschke (15048774) (author), Verena Jendrossek (15048777) (author), Marc Remke (14962619) (author), Barbara M. Grüner (14947089) (author), Alexander Roesch (15048780) (author), Jens T. Siveke (11780911) (author), Christel Herold-Mende (15047946) (author), Tobias Blau (15048783) (author), Kathy Keyvani (15048786) (author), Frank K.H. van Landeghem (15048789) (author), Torsten Pietsch (15048792) (author), Jörg Felsberg (15048795) (author), Guido Reifenberger (12335398) (author), Michael Weller (15037908) (author), Ulrich Sure (15048798) (author), Oliver Brüstle (15048801) (author), Matthias Simon (15048804) (author), Martin Glas (15048807) (author), Björn Scheffler (15048810) (author)
Pubblicazione:	2025
Soggetti:	Cancer Therapeutic Research and Development Clinical Research and Trials CNS Cancers Gliomas, Glioblastomas Drug Targets Precision Medicine
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
di: Sied Kebir (15048732)
Pubblicazione: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
di: Sied Kebir (15048732)
Pubblicazione: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
di: Sied Kebir (15048732)
Pubblicazione: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
di: Sied Kebir (15048732)
Pubblicazione: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
di: Qingsheng Xu (17078830)
Pubblicazione: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
di: Qingsheng Xu (17078830)
Pubblicazione: (2025)

Supplementary Figure S1 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Supplementary Figure S2 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Supplementary Figure S3 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Supplementary Figure S4 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Supplementary Figure S5 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Supplementary Figure S6 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Supplementary Figure S7 from Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
di: Tobias Kessler (17079209)
Pubblicazione: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
di: Bachchu Lal (17141949)
Pubblicazione: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
di: Francesca Orzan (15055579)
Pubblicazione: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
di: Francesca Orzan (15055579)
Pubblicazione: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
di: Francesca Orzan (15055579)
Pubblicazione: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
di: Defne Bayik (14961098)
Pubblicazione: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
di: Isha Mondal (16721699)
Pubblicazione: (2025)

Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
di: William Kelly (15439117)
Pubblicazione: (2025)

Supplementary Data File 2 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
di: William Kelly (15439117)
Pubblicazione: (2025)

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
di: Michael Kilian (16697663)
Pubblicazione: (2025)

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
di: Michael Kilian (16697663)
Pubblicazione: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
di: Michael Kilian (16697663)
Pubblicazione: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
di: Anne-Florence Blandin (15056366)
Pubblicazione: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
di: Mengjie Zhao (14845174)
Pubblicazione: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
di: Mengjie Zhao (14845174)
Pubblicazione: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
di: Mengjie Zhao (14845174)
Pubblicazione: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
di: Mengjie Zhao (14845174)
Pubblicazione: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
di: Mengjie Zhao (14845174)
Pubblicazione: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
di: Joseph Toker (15399882)
Pubblicazione: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
di: Joseph Toker (15399882)
Pubblicazione: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
di: Joseph Toker (15399882)
Pubblicazione: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
di: Joseph Toker (15399882)
Pubblicazione: (2025)

Cannot write session to /tmp/vufind_sessions/sess_3phsr7398qfvj76h5uaamkl84v